Novartis Returns to Growth in the Third Quarter

Novartis reported a 4% sales increase to $14.5B in Q3, returning to growth after Q1 declines. Operating profit fell 59% to $1.8B due to a $1.9B impairment charge for a failed drug. Core operating profit rose to $6.0B, exceeding estimates. The company adjusted its full-year profit guidance to stable or slight growth.

Original reporting
Published Oct 27, 2026, 6:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 7:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novartis Returns to Growth in the Third Quarter — source image
Decision brief

The 30-second read

$NVSNeutralHigh
01

Why it matters

The earnings release provides fresh data on revenue growth and profit margins, influencing valuation models.

02

Market read

The report updates expectations for Novartis and may affect healthcare sector sentiment.

03

What to watch

Potential cost‑cutting measures and pipeline progress could mitigate the profit decline.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Novartis, a Basel‑based pharma giant, disclosed its Q3 2026 results, highlighting sales growth, a large impairment, and updated guidance.

Company-level read

Ticker impact

$NVSNeutralHigh confidence
Context

Novartis reported Q3 sales of $14.5B and a core operating profit of $6.0B, beating consensus and updating full-year guidance.

Expected impact

likely modest downside as the profit drop may pressure the stock despite the core profit beat.

Evidence & confidence

The impairment charge signals near‑term earnings weakness, outweighing the core profit beat.

Market effects

Pharma sector may see mixed reactions as other peers face similar generic erosion pressures.

European markets could be slightly pressured by the earnings miss on operating profit.

Limited; impact confined to healthcare investors.

Counterpoint

Core profit beat suggests underlying growth; the impairment may be a one‑off, offering a buying opportunity.

Key entities

  • Novartis

    Swiss pharmaceutical company reporting Q3 results.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$NVSMedAI 8/10

Novartis Trims Growth Target at Annual Management Day, Shares Slide

Novartis reduced its mid-term sales growth outlook to 5% annually from 2026-2031, down from a prior 5-6% range. Shares fell 3% on the news. The revision follows patent expirations and clinical trial failures, including a $2.2B writedown. Despite this, Novartis raised peak sales forecasts for three key drugs: Kesimpta, Scemblix, and Leqvio. The company expects growth beyond 2031 from internally developed medicines, with 10 in late-stage development.

$NVSMed

Novartis trims medium-term growth target, shares fall

Novartis reduced its annual sales growth target to 5% through 2031, down from a previous range of 5%-6%. Shares fell 3.3% after the announcement, which came amid patent expirations and clinical trial setbacks. The company expects growth from existing drugs like Kesimpta, Scemblix, and Leqvio, with no large acquisitions planned. Analysts anticipate growth slowing post-2030 due to competition for key drugs.